Literature DB >> 22622516

BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.

Jai-Hyun Kim1, Matthew R Peacock, Steven C George, Christopher C W Hughes.   

Abstract

ALK1 (ACVRL1) is a member of the TGFβ receptor family and is expressed predominantly by arterial endothelial cells (EC). Mutations in ACVRL1 are responsible for hereditary hemorrhagic telangiectasia type 2 (HHT2), a disease manifesting as fragile vessels, capillary overgrowth, and numerous arterio-venous malformations. Arterial EC also express EphrinB2, which has multiple roles in vascular development and angiogenesis and is known to be reduced in ACVRL1 knockout mice. Using an in vitro angiogenesis model we find that the Alk1 ligand BMP9 induces EphrinB2 in EC, and this is entirely dependent on expression of Alk1 and at least one of the co-receptors BMPRII or ActRII. BMP9 induces both ID1 and ID3, and both are necessary for full induction of EphrinB2. Loss of Alk1 or EphrinB2 results in increased arterial-venous anastomosis, while loss of Alk1 but not EphrinB2 results in increased VEGFR2 expression and enhanced capillary sprouting. Conversely, BMP9 blocks EC sprouting and this is dependent on Alk1, BMPRII/ActRII and ID1/ID3. Finally, notch signaling overcomes the loss of Alk1-restoring EphrinB2 expression in EC, and curbing excess sprouting. Thus, in an in vitro model of HHT2, loss of Alk1 blocks BMP9 signaling, resulting in reduced EphrinB2 expression, enhanced VEGFR2 expression, and misregulated EC sprouting and anastomosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622516      PMCID: PMC3423339          DOI: 10.1007/s10456-012-9277-x

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  57 in total

Review 1.  The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications.

Authors:  Elisabetta Dejana; Elisabeth Tournier-Lasserve; Brant M Weinstein
Journal:  Dev Cell       Date:  2009-02       Impact factor: 12.270

2.  BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.

Authors:  Marion Scharpfenecker; Maarten van Dinther; Zhen Liu; Rutger L van Bezooijen; Qinghai Zhao; Laurie Pukac; Clemens W G M Löwik; P ten Dijke
Journal:  J Cell Sci       Date:  2007-02-20       Impact factor: 5.285

3.  The unfolded protein response is necessary but not sufficient to compensate for defects in disulfide isomerization.

Authors:  Jai-Hyun Kim; Yinsuo Zhao; Xuewen Pan; Xiangwei He; Hiram F Gilbert
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

Review 4.  Arterial-venous specification during development.

Authors:  Matthew R Swift; Brant M Weinstein
Journal:  Circ Res       Date:  2009-03-13       Impact factor: 17.367

Review 5.  Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis.

Authors:  Matthew T Holderfield; Christopher C W Hughes
Journal:  Circ Res       Date:  2008-03-28       Impact factor: 17.367

6.  ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2.

Authors:  Sung O Park; Young Jae Lee; Tsugio Seki; Kwon-Ho Hong; Naime Fliess; Zhigang Jiang; Alice Park; Xiaofang Wu; Vesa Kaartinen; Beth L Roman; S Paul Oh
Journal:  Blood       Date:  2007-10-02       Impact factor: 22.113

7.  Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.

Authors:  Paul D Upton; Rachel J Davies; Richard C Trembath; Nicholas W Morrell
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

8.  Bone morphogenetic protein-9 is a circulating vascular quiescence factor.

Authors:  Laurent David; Christine Mallet; Michelle Keramidas; Noël Lamandé; Jean-Marie Gasc; Sophie Dupuis-Girod; Henri Plauchu; Jean-Jacques Feige; Sabine Bailly
Journal:  Circ Res       Date:  2008-02-28       Impact factor: 17.367

Review 9.  Hereditary haemorrhagic telangiectasia: a clinical and scientific review.

Authors:  Fatima S Govani; Claire L Shovlin
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

10.  Ephrin-B2 regulates endothelial cell morphology and motility independently of Eph-receptor binding.

Authors:  Magdalena L Bochenek; Sarah Dickinson; Jonathan W Astin; Ralf H Adams; Catherine D Nobes
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

View more
  28 in total

1.  VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.

Authors:  Chul Han; Se-Woon Choe; Yong Hwan Kim; Abhinav P Acharya; Benjamin G Keselowsky; Brian S Sorg; Young-Jae Lee; S Paul Oh
Journal:  Angiogenesis       Date:  2014-06-24       Impact factor: 9.596

Review 2.  Vascular Integrity in the Pathogenesis of Brain Arteriovenous Malformation.

Authors:  Rui Zhang; Wan Zhu; Hua Su
Journal:  Acta Neurochir Suppl       Date:  2016

3.  Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking αVβ8-TGFβ signaling in the brain.

Authors:  Thomas D Arnold; Colin Niaudet; Mei-Fong Pang; Julie Siegenthaler; Konstantin Gaengel; Bongnam Jung; Gina M Ferrero; Yoh-suke Mukouyama; Jonas Fuxe; Rosemary Akhurst; Christer Betsholtz; Dean Sheppard; Louis F Reichardt
Journal:  Development       Date:  2014-11-18       Impact factor: 6.868

Review 4.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

5.  Context-specific interactions between Notch and ALK1 cannot explain ALK1-associated arteriovenous malformations.

Authors:  Elizabeth R Rochon; Daniel S Wright; Max M Schubert; Beth L Roman
Journal:  Cardiovasc Res       Date:  2015-05-12       Impact factor: 10.787

6.  Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.

Authors:  Santiago Ruiz; Haitian Zhao; Pallavi Chandakkar; Julien Papoin; Hyunwoo Choi; Aya Nomura-Kitabayashi; Radhika Patel; Matthew Gillen; Li Diao; Prodyot K Chatterjee; Mingzhu He; Yousef Al-Abed; Ping Wang; Christine N Metz; S Paul Oh; Lionel Blanc; Fabien Campagne; Philippe Marambaud
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

7.  Endothelial signaling and the molecular basis of arteriovenous malformation.

Authors:  Deepak Atri; Bruno Larrivée; Anne Eichmann; Michael Simons
Journal:  Cell Mol Life Sci       Date:  2013-09-28       Impact factor: 9.261

8.  Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation.

Authors:  Sandrine Levet; Delphine Ciais; Galina Merdzhanova; Christine Mallet; Teresa A Zimmers; Se-Jin Lee; Fabrice P Navarro; Isabelle Texier; Jean-Jacques Feige; Sabine Bailly; Daniel Vittet
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

9.  BMP9 regulates endoglin-dependent chemokine responses in endothelial cells.

Authors:  Kira Young; Barbara Conley; Diana Romero; Eric Tweedie; Christine O'Neill; Ilka Pinz; Louise Brogan; Volkhard Lindner; Lucy Liaw; Calvin P H Vary
Journal:  Blood       Date:  2012-09-26       Impact factor: 22.113

10.  Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans.

Authors:  Kyoko Kawasaki; Julia Freimuth; Dominique S Meyer; Marie M Lee; Akiko Tochimoto-Okamoto; Michael Benzinou; Frederic F Clermont; Gloria Wu; Ritu Roy; Tom G W Letteboer; Johannes Kristian Ploos van Amstel; Sophie Giraud; Sophie Dupuis-Girod; Gaeten Lesca; Cornelius J J Westermann; Robert J Coffey; Rosemary J Akhurst
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.